Related Experiment Video

Updated: May 29, 2026

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer
10:36

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

Pharmacogenetics of anti-estrogen treatment of breast cancer

Marzia Del Re1, Angela Michelucci, Paolo Simi

  • 1Division of Pharmacology, Department of Internal Medicine, University of Pisa, Italy.

Cancer Treatment Reviews
|September 16, 2011
PubMed

Insights

Genetic screening for tamoxifen metabolism may guide breast cancer treatment. While CYP2D6 variants impact drug efficacy, routine genetic testing is debated but could aid selected patients.

Area of Science:

  • Pharmacogenomics
  • Oncology
  • Drug Metabolism

Background:

  • Tamoxifen is a key endocrine therapy for breast cancer.
  • Host genetic factors influence tamoxifen's metabolism and clinical outcomes.
  • Cytochrome P450 2D6 (CYP2D6) is crucial for converting tamoxifen to its active form, endoxifen.

Purpose of the Study:

  • To evaluate the clinical relevance of genetic polymorphisms in drug-metabolizing enzymes for endocrine therapy in breast cancer.
  • To assess the role of CYP2D6 and UDP-glucuronosyltransferases in tamoxifen efficacy and safety.

Main Methods:

  • Review of scientific literature on genetic variations affecting tamoxifen metabolism.
  • Analysis of the impact of CYP2D6 and UDP-glucuronosyltransferase polymorphisms on endoxifen levels and treatment outcomes.

Main Results:

  • CYP2D6 genetic variants can lead to reduced endoxifen levels, potentially decreasing tamoxifen's benefits.
  • Data on routine CYP2D6 analysis for tamoxifen treatment is not yet conclusive.
  • UDP-glucuronosyltransferases also play a role in tamoxifen and aromatase inhibitor metabolism, influencing clinical outcomes.

Conclusions:

  • The utility of routine pharmacogenetic profiling before tamoxifen initiation is under debate.
  • Genetic screening may offer valuable support for clinical decision-making in specific breast cancer patient populations.
  • Further research is needed to establish definitive guidelines for pharmacogenetic testing in endocrine therapy.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...